Allterum Therapeutics completes Series Seed offering, builds team with addition of Philip Breitfeld as Chief Medical Officer
News provided by
Share this article
Share this article
HOUSTON, Dec. 17, 2020 /PRNewswire/ Allterum Therapeutics, Inc. completed its $1.8 million Series Seed offering to members of the FanninDirect
SM investor group. Allterum is developing a novel immunotherapy for treatment of IL7R-expressing cancers, including difficult to treat cases of pediatric acute lymphoblastic leukemia (ALL), a program which has received both Orphan Drug and Rare Pediatric Disease Designations from FDA. The company will use the proceeds for its pre-clinical antibody manufacturing and toxicology work and to continue to build the management team.